Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Appointments Committee's proposal for the composition of Raute Corporation's Board of Directors

RAUTE CORPORATION STOCK EXCHANGE RELEASE 25 FEBRUARY 2022 at 10:10 a.m.    APPOINTMENTS COMMITTEE’S PROPOSAL FOR THE COMPOSITION OF RAUTE CORPORATION’S BOARD OF DIRECTORS   Raute Corporation’s Appointments Committee has announced that it will propose to the Annual General Meeting, which will convene on March 31, 2022, that the number of Board members be increased from the current six members to seven members. The Appointments Committee has considered that the company’s international growth and business development goals can be better supported by reinforcing the Board.

Hexagon Agility receives order from RenewGas Transportation for Mobile Pipeline® modules to deliver renewable natural gas

Hexagon Agility has received an order for Mobile Pipeline[®] TITAN[®] modules from RenewGas Transportation, a leading provider of complete turnkey transportation solutions for renewable natural gas (RNG). These modules will be used to transport and deliver RNG derived from agricultural waste.   The order represents an estimated value of USD 5.5 million (approx. NOK 49.5 million) for delivery in Q4 2022 thru Q1 2023. “We’ve built our mobile pipeline fleet around Hexagon Agility’s TITAN modules, which are essential to our growth in the RNG market, the cleanest solution available to

BioStock: Pila Pharma’s CEO on building the company since its IPO

“We’re on our way.” This is how Pila Pharma CEO Dorte X. Gram starts the 2021 year end report that was released last week. During the first half of the year as a public company, the focus has been on building the high-quality team that will drive the development of the drug candidate XEN-D0501, hopefully all the way to market. In connection with the newly released report, BioStock has contacted Gram to get her view of the past year.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/pila-pharmas-ceo-on-building-the-company-since-its-ipo/This is a press release from

Success for Axfood’s sustainability efforts in 2021

In conjunction with the publication of Axfood’s Annual and Sustainability Report for 2021, the following summary of improvements in the Group’s sustainability efforts is presented. Examples of the important progress made during the year include a continued reduction of food waste, lower emissions from own operations and the fact that all of the Group’s 262 trucks can now be powered by fossil-free fuel.“There are no shortcuts when it comes to successful sustainability work. While the challenges are growing in number, it is important to address all of the areas impacted by the Group’s

Heliospectra carries out share issues by way of set-off totalling approximately SEK 13.1 million

(Gothenburg, Sweden February 25, 2022, at 09:00 CET) The board of directors of Heliospectra AB (publ) (the “Company” or “Heliospectra”) has today, pursuant to the authorization granted by the Annual General Meeting on 20 May 2021, resolved upon directed issues of shares totalling approximately SEK 13.1 million (the “Directed Issues”), to three of the Company’s main shareholders, i.e., Weland Stål AB, ADMA Förvaltnings AB, and Corespring New Technology AB (the “Main Owner(s)”). The subscription price amounts to approximately SEK 1.53 per share. The issue funds have been paid by set-off of

Discussion event for shareholders on YIT’s events and financial statements in 2021

YIT Corporation Investor news 25 February 2022 at 10:00 a.m.Discussion event for shareholders on YIT’s events and financial statements in 2021 A discussion event related to YIT's 2021 events and financial statements will be held on Monday 28 February 2022 at 3.00 p.m. Finnish time (EET, at 1.00 p.m. GMT). In the event, the shareholders can ask questions from the Chairman of the Board and the President and CEO before the registration and advance voting of the Annual General Meeting. Shareholder are requested to take into consideration that the questions asked at the informal discussion

DanCann Pharma A/S publishes Q4-2021 report

COPENHAGEN, Denmark, 25 February 2022 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby today releases its results for the period 1 October – 31 December 2021 (the “period”). The Q4-2021 report is available as an attached document to this press release and at www.dancann.com.Group key figures Q4 2021 KDKK 01/10/21 01/10/20 31/12/20 01/01/21 31/12/21 01/01/20 31/12/20 31/12/21Net sales 874 0 874 0Operating -4,718 -2,721 -14,509 -5,871

RLS GLOBAL AB (publ) YEAR-END REPORT, Q4, 2021

OCTOBER 1[st ]– DECEMBER 31[st] (previous year in brackets) · Net sales amounted to TSEK 219 (TSEK 139) · Earnings before interest and taxes (EBIT) amounted to TSEK -7 478 (TSEK -7 655) · Earning per share before dilution at SEK -0,11 (SEK -0,12) · Cash flow from operating activities amounted to TSEK -4 887 (TSEK -7 000) · Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997) · Equity ratio was 75 % (87 %).  JANUARY 1[st ]– DECEMBER 31[st] (previous year in brackets) · Net sales amounted to TSEK 653 (TSEK 2 043)                      · Earnings

Wulff Group Plc: Manager Transaction - Elina Pienimäki

MANAGERS’ TRANSACTIONS  FEBRUARY 25, 2022 AT 10.00 A.M.  Wulff Group Plc has disposed on 23 February 2022 it’s own shares as a part of Wulff Group Plc’s short-term incentive scheme according to the decision by the Board of Directors on 21 February 2022. Detailed information about the transaction is given in the table below.   Name: Elina PienimäkiPosition: CEOIssuer: Wulff Group PlcLEI: 74370016PW2V4W02LX91Notification type: Initial notificationReference number: 10420/5/4

Notice of Indutrade AB's 2022 Annual General Meeting

The Annual General Meeting of Indutrade Aktiebolag (publ) (reg. no. 556017-9367) will be held on Tuesday, 5 April 2022.This is a non-official translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail.Due to the coronavirus, Indutrade has decided that the Annual General Meeting shall be conducted without the physical presence of shareholders, representatives or third parties, and that shareholders shall have the opportunity to exercise their voting rights only by postal voting. Information on

Axfood publishes Annual and Sustainability Report 2021

Axfood’s Annual and Sustainability Report 2021 has been published and is now available on the Group’s website.– As we now put 2021 behind, I can confidently say that the past year has probably been the most intense and exceptional year in Axfood’s history. Despite operating in the midst of a pandemic, with restrictions and a number of upheavals, we strengthened our market positions and implemented major structural changes that are increasing our competitiveness. The developments we are now implementing are creating the prerequisites for long-term, profitable and sustainable growth, says

Year-end report 2021

Gradientech AB (publ) year-end report for 2021 is now available on the company's website www.gradientech.se.Fourth quarter October-December 2021 · Net sales amounted to 0 KSEK (24 KSEK). · Net profit amounted to -17,860 KSEK (-10,036 KSEK). · Earnings per share were SEK -1.46 (SEK -1.03). · Cash flow from operating activities amounted to -17,288 KSEK (-9,876 KSEK). · Cash and cash equivalents on the balance sheet date amounted to 14,724 KSEK (71,154 KSEK). · Equity as of December 31 amounted to 93,770 KSEK (75,760 KSEK). · The annual external audit (bsi) of the

Resqunit AB - 2021 Fourth Quarter Report

Resqunit AB today announced fourth quarter 2021 results. "Project developments over the past months have further strengthened our belief in the tremendous growth potential. 2021 has largely been focused around R&D activities and prototype field testing with several partners around the world. During the fourth quarter, our main product line-up has been established and are being prepared for mass-production. We're confident that this will result in strong growth in the time to come," says Helge Trettø Olsen, CEO of Resqunit AB.Net sales amounted to SEK 67 thousand for the year 2021, a

Eevia Health Plc Interim Report Quarter 4 – 2021

THE BOARD AND CEO OF EEVIA HEALTH PLC PRESENT THE YEAR-END REPORT FOR JANUARY 1 – DECEMBER 31, 2021, INCLUDING THE INTERIM REPORT FOR THE FOURTH QUARTER OF 2021.Significant events during the fourth quarter and full-year 2021: · Net sales for the year grew by over 130% compared to 2020, amounting to the total revenue of KEUR 6,671. · During Q4, 2021 Net sales amounted to KEUR 658 compared to KEUR 1,534 in 2020. The underlying Net Sales in Q4, 2021 was KEUR 801. The underlying revenue was higher than the reported revenue. Eevia credited one sold batch in Q4-21 that needed reprocessing.

Heliospectra (publ) Publish Year-End Report 2021

(Gothenburg, Sweden February 25, 2022, at 08:45 CET)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Year-End Report for 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT Financial Performance for the period October - December and January – December Order intake during the period October - December amounted to SEK 4,248 (9,440) thousand. For

STENOCARE enters the UK market with three medical cannabis oil products

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) to make medical cannabis oil products available for UK patients. With this STENOCARE is taking a major step towards its goal of becoming a European market leader. STENOCARE has been working extensively on the regulatory approval in the UK and considers the current timing to be good given that industry analysts have projected that the UK will become one of Europe’s largest markets in five years. Delivery of first products to the UK market is expected in 60-90 days.This information is

BioStock: Cereno Scientific strengthens R&D organisation

Swedish biotech Cereno Scientific has recruited Fredrik Frick as Head of Clinical Operations. The addition to the company’s executive management team further strengthens its R&D organisation, as Cereno eyes a scenario with up to three clinical programmes in its pipeline by 2023.Read the article at biostock.se: https://www.biostock.se/en/2022/02/cereno-scientific-strengthens-rd-organisation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Hamlet Pharma AB Interim Report Q2; October – December 2021

Opening remarks The second quarter of the fiscal year 2021/2022 has been very productive ending on a high with the completion of the clinical part of the dose-escalation study in December. The positive outcome was communicated in January 2022, showing stronger effects on the tumors with higher doses of Alpha1H. No drug related side effects were detected, further strengthening the profile of Alpha1H as a drug candidate with a high level of tumor specificity. These findings inspire us to proceed with the drug development towards Phase III trials. The dialogue with our US partners Target

Pharmacolog's Year-end Bulletin 2020

Press release: Uppsala, February 25, 2022. Pharmacolog i Uppsala AB’s (publ) Year-end Bulletin 2021 is now available on the company’s webbsite www.pharmacolog.com (Swedish only)Fjärde kvartalet 1 oktober – 31 december 2021 · Koncernens nettoomsättning för perioden uppgick till 3 838 (866) KSEK. · Rörelseresultatet för koncernen för perioden uppgick till -2 976 (-4 449) KSEK. · Nettoresultat per aktie före och efter utspädning var för perioden -0,20 (-0,35) SEK. Perioden 1 januari – 31 december 2021 · Koncernens nettoomsättning för perioden uppgick till 8 816 (1 901) KSEK.

YEAR END REPORT Period from January 2021 to December 2021

Peptonic Medical Israel Ltd and CommonSense Marketing Inc is consolidated in the group from 2021-10-20 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) Group, Peptonic Medical Israel Ltd and CommonSense Marketing Inc are included from 2021-10-20 2021 FOURTH QUARTER (Oct-Dec) · Net sales of products KSEK 5,642 (7,258) · Gross profit KSEK 3,388 (3,866), Gross margin 60% (53%) · Operating loss KSEK -43,974 (-10,702)  · Loss per share SEK -0.23 (-0.07) FULL YEAR 2021 (Jan-Dec) · Net sales of products KSEK 31,643 (21,283) · Gross

Quartiers Properties’ Year-End Report – January to December 2021

Today Quartiers Properties AB (publ) published the company’s year-end report for the period January to December 2021Summary of the period THE PERIOD OCTOBER – DECEMBER 2021 · Net sales for the fourth quarter totalled SEK 49,784 (10,131) thousand. · The company's cash flow from operating activities, including the sale of housing, amounted to SEK 24,549 (-17,051) thousand. · Revenue from the operator business, including Boho Club and the company's apartment rental business, amounted toSEK 15,883 (6,653) thousand, corresponding to an increase of SEK 9,230 thousand, or 139%

There are no items matching the current filter
There are no more items matching the current filter
Back to top